The importance of planned dose of chemotherapy on time: Do we need to change our clinical practice?

Oncologist

Volumn 3, Issue 5, 1998, Pages 365-368

  Foote, Maryann ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE; VINDESINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; HUMAN; LYMPHOMA; MASTECTOMY; PRIORITY JOURNAL; REVIEW;

EID: 0031764186     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-5-365     Document Type: Review

References (12)

1. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-2508.
2. DeVita VT Jr. Principles of cancer management: chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia: Lippincott-Raven, 1997;333-347.
3. Skipper HE. Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res 1967;27:2636-2645.
4. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24(suppl 10):S3-S10.
5. Skipper H. Data and analyses having to do with the influence of dose intensity and duration of treatment (single drugs and combinations) on lethal toxicity and therapeutic response of experimental neoplasms. Southern Research Institute 1986; Booklet 13.
6. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162-1170.
7. Hryniuk WM, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1287.
8. Hryniuk W. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65-74.
9. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988;6:1501-1515.
10. Hryniuk W, Frei E, Wright F. A single scale for measuring dose intensity of all chemotherapy regimens in breast cancer: summation dose intensity. Proc Am Soc Clin Oncol 1998;17:114a.
11. Tannock IF, Boyd MF, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377-1387.
12. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259.